MG-132

Catalog No.S2619

Molecular Weight(MW): 475.62

MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

Selleck's MG-132 had a noticeably greater effect when compared with similar products from Sigma: This is directly due to using the (S, R, S) - (-) - 2 configuration.

P21 protein can be degraded through ubiquitylation pathway. Inhibition of proteasome activities results in the accumulation of P21 protein, therefore, the more powerful the inhibiting effect, the more P21 protein is accumulated. (testing protein: P21; Cell line: Hela; treatment condition: final concentration of MG-132 is 5μM, with a 6 hour treatment time)

Cited by 180 Publications

Nature, 2019, 567(7747):262-266

PubMed: 30842662 ( click the link to review the publication )

Nature, 2019, 565(7741):659-663

PubMed: 30675059 ( click the link to review the publication )

Science, 2019, 363(6434)

PubMed: 30923196 ( click the link to review the publication )

Cell, 2019, 177(3):766-781

PubMed: 30955882 ( click the link to review the publication )

Cell, 2019, 176(3):505-519

PubMed: 30612738 ( click the link to review the publication )

Nature, 2018, 556(7702):501-504

PubMed: 29670287 ( click the link to review the publication )

Cell Stem Cell, 2018, 22(3):369-383

PubMed: 29499153 ( click the link to review the publication )

Cancer Cell, 2017, 31(6):790-803

PubMed: 28609657 ( click the link to review the publication )

Nature, 2016, 532(7599):389-93

PubMed: 27064903 ( click the link to review the publication )

Nature, 2015, 528(7582):422-6

PubMed: 26649820 ( click the link to review the publication )

Acta Neuropathol, 2019, 138(1):67-84

PubMed: 30937520 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(9):4765-4777

PubMed: 30843071 ( click the link to review the publication )

Autophagy, 2019, 1-13

PubMed: 30957628 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-4145

PubMed: 31285371 ( click the link to review the publication )

Dev Cell, 2019, 50(3):367-380

PubMed: 31178402 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2853-2864

PubMed: 30940659 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-4055

PubMed: 31118200 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.206227

PubMed: 30872372 ( click the link to review the publication )

Theranostics, 2019, 9(3):796-810

PubMed: 30809309 ( click the link to review the publication )

Cell Rep, 2019, 26(11):3076-3086.e6

PubMed: 30865895 ( click the link to review the publication )

Mucosal Immunol, 2019, 10.1038/s41385-019-0178-9

PubMed: 31182817 ( click the link to review the publication )

Redox Biol, 2019, 22:101131

PubMed: 30735911 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(12):2079-2094

PubMed: 30825187 ( click the link to review the publication )

Cancer Lett, 2019, 442:68-81

PubMed: 30409762 ( click the link to review the publication )
Cancer Lett, 2019, 442:137-147

PubMed: 30420335 ( click the link to review the publication )

J Med Chem, 2019, 62(2):941-964

PubMed: 30629437 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):280

PubMed: 31253190 ( click the link to review the publication )

Cell Death Dis, 2019, 10(3):191

PubMed: 30804329 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):314

PubMed: 30952840 ( click the link to review the publication )

Cells, 2019, 8(5)

PubMed: 31083332 ( click the link to review the publication )

Exp Mol Med, 2019, 51(7):83

PubMed: 31337751 ( click the link to review the publication )

FASEB J, 2019, 10.1096/fj.201802440R

PubMed: 31017817 ( click the link to review the publication )

FASEB J, 2019, 33(4):5366-5376

PubMed: 30759345 ( click the link to review the publication )

Hum Mutat, 2019, 40(4):392-403

PubMed: 30609140 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(2):771-782

PubMed: 30694217 ( click the link to review the publication )

Int J Cancer, 2019, 144(3):582-594

PubMed: 30289973 ( click the link to review the publication )

Cancer Sci, 2019, 110(4):1268-1278

PubMed: 30689267 ( click the link to review the publication )

Cancer Sci, 2019, 110(4):1268-1278

PubMed: 30689267 ( click the link to review the publication )

J Immunol, 2019, 203(1):269-281

PubMed: 31092637 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(1):293-305

PubMed: 30394687 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(2):253-264

PubMed: 30745818 ( click the link to review the publication )

Food Chem Toxicol, 2019, 131:110537

PubMed: 31150782 ( click the link to review the publication )

Endocrinology, 2019, 10.1210/en.2019-00107

PubMed: 31199479 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:175

PubMed: 31320837 ( click the link to review the publication )

Gene, 2019, 707:86-92

PubMed: 31071385 ( click the link to review the publication )

Front Pharmacol, 2019, 10:421

PubMed: 31068817 ( click the link to review the publication )

J Proteomics, 2019, 192:334-345

PubMed: 30268636 ( click the link to review the publication )

Drug Metab Dispos, 2019, 47(4):425-435

PubMed: 30745309 ( click the link to review the publication )
Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0248-2

PubMed: 31171828 ( click the link to review the publication )

Life Sci, 2019, 225:64-71

PubMed: 30953640 ( click the link to review the publication )

Virology, 2019, 530:51-58

PubMed: 30780125 ( click the link to review the publication )

Phytother Res, 2019, 33(7):1837-1850

PubMed: 31050072 ( click the link to review the publication )

Mol Immunol, 2019, 108:45-55

PubMed: 30780033 ( click the link to review the publication )

Eur J Pharmacol, 2019, 846:1-11

PubMed: 30639309 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 510(3):364-369

PubMed: 30712944 ( click the link to review the publication )

Microb Pathog, 2019, 132:51-58

PubMed: 31028862 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 514(4):1270-1277

PubMed: 31113618 ( click the link to review the publication )

Clin Transl Oncol, 2019, 10.1007/s12094-019-02152-5

PubMed: 31218648 ( click the link to review the publication )

Exp Hematol, 2019, 72:36-46

PubMed: 30611870 ( click the link to review the publication )

Exp Ther Med, 2019, 18(1):621-629

PubMed: 31258698 ( click the link to review the publication )

J Vis Exp, 2019, 10.3791/59472

PubMed: 31157769 ( click the link to review the publication )

J Pathol, 2019, 247(2):266-278

PubMed: 30357833 ( click the link to review the publication )

Neurotherapeutics, 2019, 10.1007/s13311-019-00759-8

PubMed: 31313223 ( click the link to review the publication )

J Clin Invest, 2018, 128(7):2877-2893

PubMed: 29863498 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4029

PubMed: 30279413 ( click the link to review the publication )

Cancer Res, 2018, 78(11):2886-2896

PubMed: 29572225 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):183

PubMed: 30081903 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):21

PubMed: 29343814 ( click the link to review the publication )

Cell Death Dis, 2018, 9(5):553

PubMed: 29748582 ( click the link to review the publication )

FASEB J, 2018, 10.1096/fj.201800109R

PubMed: 29763381 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):931-942

PubMed: 29440449 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(9):1750-1765

PubMed: 29915147 ( click the link to review the publication )
Biochim Biophys Acta Mol Cell Res, 2018, 1865(8):1105-1113

PubMed: 29758299 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

Apoptosis, 2018, 23(1):54-64

PubMed: 29256070 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:2905-2914

PubMed: 30214285 ( click the link to review the publication )

Int J Oncol, 2018, 52(4):1105-1116

PubMed: 29436617 ( click the link to review the publication )

J Cell Biochem, 2018, 119(1):948-959

PubMed: 28681940 ( click the link to review the publication )

Oncol Rep, 2018, 39(6):2951-2959

PubMed: 29658600 ( click the link to review the publication )

Eur J Pharmacol, 2018, 830:17-25

PubMed: 29680228 ( click the link to review the publication )

FEBS Lett, 2018, 592(19):3286-3294

PubMed: 30136317 ( click the link to review the publication )

Biochemistry, 2018, 57(31):4663-4674

PubMed: 29474059 ( click the link to review the publication )

Vet Microbiol, 2018, 223:134-143

PubMed: 30173739 ( click the link to review the publication )

Biol Res, 2018, 51(1):53

PubMed: 30497519 ( click the link to review the publication )

Mol Med Rep, 2018, 18(1):1206-1210

PubMed: 29845253 ( click the link to review the publication )

Cell, 2018, 175(5):1336-1351

PubMed: 30318148 ( click the link to review the publication )

Mol Cell, 2017, 68(6):1134-1146

PubMed: 29225033 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):107

PubMed: 28797284 ( click the link to review the publication )

Cell Death Dis, 2017, 8(2):e2607

PubMed: 28182012 ( click the link to review the publication )

Mol Oncol, 2017, 11(12):1806-1825

PubMed: 29094484 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2017, 1864(7):1195-1206

PubMed: 28315713 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(12):3641-3657

PubMed: 28726275 ( click the link to review the publication )

J Biol Chem, 2017, 292(26):10779-10790

PubMed: 28515316 ( click the link to review the publication )

Mol Pharmacol, 2017, 91(5):438-450

PubMed: 28275049 ( click the link to review the publication )

BMC Genomics, 2017, 18(1):127

PubMed: 28166733 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(1):20-34

PubMed: 28760737 ( click the link to review the publication )
Int J Oncol, 2017, 50(3):883-892

PubMed: 28197637 ( click the link to review the publication )

Mol Brain, 2017, 10(1):7

PubMed: 28196470 ( click the link to review the publication )

Life Sci, 2017, 173:36-42

PubMed: 28212825 ( click the link to review the publication )

Int J Oncol, 2017, 50(2):373-380

PubMed: 28035348 ( click the link to review the publication )

Chem Biol Interact, 2017, 273:228-236

PubMed: 28651835 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(2):398-405

PubMed: 28315332 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 484(4):753-761

PubMed: 28153731 ( click the link to review the publication )

BMC Mol Biol, 2017, 18(1):13

PubMed: 28506294 ( click the link to review the publication )

Cell, 2017, 170(3):564-576

PubMed: 28753430 ( click the link to review the publication )

Immunity, 2016, 45(4):944

PubMed: 27760343 ( click the link to review the publication )

Blood, 2016, 127(8):1007-16

PubMed: 26675346 ( click the link to review the publication )

Nat Commun, 2016, 7:11123

PubMed: 27030211 ( click the link to review the publication )

Nat Commun, 2016, 7:12044

PubMed: 27375289 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(10):4745-62

PubMed: 26939887 ( click the link to review the publication )

Cancer Res, 2016, 76(12):3531-40

PubMed: 27197154 ( click the link to review the publication )

Theranostics, 2016, 6(12):2209-2224

PubMed: 27924158 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.21032

PubMed: 28005008 ( click the link to review the publication )

Free Radic Biol Med, 2016, 99:54-62

PubMed: 27480846 ( click the link to review the publication )

Exp Mol Med, 2016, 48:e225

PubMed: 27034027 ( click the link to review the publication )

J Mol Cell Cardiol, 2016, 101:1-10

PubMed: 27789289 ( click the link to review the publication )

J Virol, 2016, 90(2):682-93

PubMed: 26491168 ( click the link to review the publication )

Environ Pollut, 2016, 218:770-782

PubMed: 27511439 ( click the link to review the publication )

Am J Pathol, 2016, 186(11):2857-2868

PubMed: 27639166 ( click the link to review the publication )

Mol Cell Biol, 2016, 36(18):2360-73

PubMed: 27354062 ( click the link to review the publication )
Toxicol Appl Pharmacol, 2016, 305:267-73

PubMed: 27342729 ( click the link to review the publication )

Int J Oncol, 2016, 48(4):1710-20

PubMed: 26892093 ( click the link to review the publication )

Cell Signal, 2016, 28(4):284-93

PubMed: 26795954 ( click the link to review the publication )

Virology, 2016, 498:116-127

PubMed: 27567260 ( click the link to review the publication )

Int J Oncol, 2016, 48(4):1639-49

PubMed: 26892350 ( click the link to review the publication )

Am J Transl Res, 2016, 8(8):3471-81

PubMed: 27648137 ( click the link to review the publication )

Infect Immun, 2016, 84(1):99-107

PubMed: 26483404 ( click the link to review the publication )

Int J Mol Med, 2016, 37(2):415-22

PubMed: 26743567 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0151147

PubMed: 26954017 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0163174

PubMed: 27658027 ( click the link to review the publication )

PLoS One, 2016, 11(8):e0160092

PubMed: 27526027 ( click the link to review the publication )

Assay Drug Dev Technol, 2016, 14(7):395-406

PubMed: 27552144 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13984-4001

PubMed: 26910887 ( click the link to review the publication )

Oncotarget, 2016, 7(27):41445-41459

PubMed: 27213590 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(1):95-103

PubMed: 25438054 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.30

PubMed: 25753158 ( click the link to review the publication )

Hepatology, 2015, 10.1002/hep.28372

PubMed: 26606000 ( click the link to review the publication )

Autophagy, 2015, 11(8):1216-29

PubMed: 26018823 ( click the link to review the publication )

Autophagy, 2015, 10.1080/15548627.2015.1023982

PubMed: 25906440 ( click the link to review the publication )

Neuro Oncol, 2015, 17(4):526-35

PubMed: ( click the link to review the publication )

Cell Rep, 2015, 10.1016/j.celrep.2015.04.049

PubMed: 26027934 ( click the link to review the publication )

FASEB J, 2015, 10.1096/fj.14-265090

PubMed: 25667221 ( click the link to review the publication )

J Cell Sci, 2015, 10.1242/jcs.168377

PubMed: 25972344 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074/jbc.M115.649640

PubMed: 25869127 ( click the link to review the publication )
Mol Cell Biol, 2015, 35(5):778-88

PubMed: ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25817892 ( click the link to review the publication )

J Agric Food Chem, 2015, 63(22):5468-75

PubMed: 25978654 ( click the link to review the publication )

Biomedicines, 2015, 3, 182-200

PubMed: ( click the link to review the publication )

Sci Rep, 2015, 5:9730

PubMed: 25856282 ( click the link to review the publication )

Viruses, 2015, 7(4):1668-84

PubMed: 25848801 ( click the link to review the publication )

Tumour Biol, 2015, 36(12):9347-56

PubMed: 26108995 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(1):458-74

PubMed: 24057215 ( click the link to review the publication )

Cancer Res, 2014, 74(24):7487-97

PubMed: 25512388 ( click the link to review the publication )

Mol Cancer, 2014, 13:94

PubMed: 24775809 ( click the link to review the publication )

Free Rad Biol Med, 2014, 10.1016/j.freeradbiomed.2014.04.010

PubMed: ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(5):1067-77

PubMed: 24674886 ( click the link to review the publication )

Annals of Clinical and Translational Neurology, 2014, 1(7): 462–470

PubMed: ( click the link to review the publication )

J Am Heart Assoc, 2014, 3(1):e000520

PubMed: 24572252 ( click the link to review the publication )

J Cell Sci, 2014, 127(21):4567-73

PubMed: 25179604 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 2):455-64

PubMed: 24213533 ( click the link to review the publication )

J Virol, 2014, 87(23):13035-41

PubMed: 24027330 ( click the link to review the publication )

Biochem Pharmacol, 2014, 91(2):157-67

PubMed: 25069048 ( click the link to review the publication )

J Biol Chem, 2014, 289(12):8277-87

PubMed: 24492612 ( click the link to review the publication )

J Proteome Res, 2014, 13(5):2223-38

PubMed: 24669782 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(16):3132-43

PubMed: 24912674 ( click the link to review the publication )

Int J Oncol, 2014, 46(1):395-406

PubMed: 25353373 ( click the link to review the publication )

Am J Physiol Regul Integr Comp Physiol, 2014, 307(11):R1330-7

PubMed: 25274907 ( click the link to review the publication )
PLoS One, 2014, 9(1):e87281

PubMed: 24489888 ( click the link to review the publication )

EMBO Mol Med, 2013, 5(3):397-412

PubMed: 23381957 ( click the link to review the publication )

J Immunol, 2013, 192(1):492-502

PubMed: 24307739 ( click the link to review the publication )

J Biol Chem, 2013, 288(10):7182-92

PubMed: 23344961 ( click the link to review the publication )

PLoS One, 2013, 8(6):e68065

PubMed: 23799156 ( click the link to review the publication )

Biol Open, 2013, 2(5):479-86

PubMed: 23789096 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Plant Physiol, 2012, 160(1):118-34

PubMed: 22732244 ( click the link to review the publication )

Chem-bio Interact, 2012, 200(1):1-10

PubMed: 22964297 ( click the link to review the publication )

FEBS Lett, 2012, 586(21):3787-92

PubMed: 23010592 ( click the link to review the publication )

PLoS One, 2012, 7(1):e29541

PubMed: 22235305 ( click the link to review the publication )

J Biol Chem, , 291(24):12871-9

PubMed: 27129200 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description

MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

Targets

Proteasome ^[9]
(Cell-free assay)

100 nM

In vitro

MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. ^[1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. ^[2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. ^[3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. ^[4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). ^[5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. ^[6]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
LPS-stimulated RAW264.7 cells	NH3l[2ZHfW6ldHnvckBCe3OjeR?=	NHTjbnozPSEQvF2=		NGHpNmJFVVOR	NEWy[JlKdmirYnn0d{BvcXS{aXOgc5hq\GVicILv[JVkfGmxbjD3bZRpKEmFNUCgc4YhOC5zIN88US=>	Mn7INlQ3QTd2OU[=
HL-60	NGLMXmZEgXSxdH;4bYMhSXO\|YYm=	MV20NEDPxE1?	M3nXT\|Q5KGh?	NHuxfllFVVOR	MlH6TWM2ODxzMDFOwG0>	M1rIPFI1Pjl5NEm2
SMMC-7721	NGO5NWZEgXSxdH;4bYMhSXO\|YYm=	MY[0NEDPxE1?	NHHLeYI1QCCq	NGDQVXhFVVOR	NXntV29QUUN3ME23MlEh\|ryP	MUKyOFY6PzR7Nh?=
A-549	MnfsR5l1d3SxeHnjJGF{e2G7	M1LWWVQxKM7:TR?=	Mn;POFghcA>?	NY[5SW8xTE2VTx?=	NHf6c\|lKSzVyPEGwJO69VQ>?	NHzzdGMzPDZ7N{S5Oi=>
MCF-7	NYW3U\|hIS3m2b4TvfIlkKEG\|c3H5	M4nmcVQxKM7:TR?=	Mn;4OFghcA>?	M{fWfGROW09?	MWrJR\|UxRTdwMzFOwG0>	MoPnNlQ3QTd2OU[=
SW-480	MVzDfZRwfG:6aXOgRZN{[Xl?	NFraV2U1OCEQvF2=	M{n3[lQ5KGh?	MmXuSG1UVw>?	NXf5fnc6UUN3ME20JO69VQ>?	M{\HTVI1Pjl5NEm2
NCI-H929	NWHy[Y1tS3m2b4TvfIlkKEG\|c3H5	M13SPFEh\|ryP	MoiwO\|IhcA>?	NHfzc3NFVVOR	NWDiU3NLUUN3ME2wMlE4KM7:TR?=	MV:yOFYzPTB6OB?=
293T	M3fldGN6fG:2b4jpZ{BCe3OjeR?=	NH7KepoyOCEQvF2=	NYH6UGxxPzJiaB?=	M{OxOWROW09?	NHvufm9KSzVyPEKg{txO	MkjLNlQ3OjVyOEi=
293T	M4rS[WZ2dmO2aX;uJGF{e2G7	MmC0NVAh\|ryP	NFrnOHQzPCCq	MYTEUXNQ	MlziUY9l\XKjdHXsfUBqdmS3Y3XzJIhm[XRvc3jvZ4shKA>?	M1Ha[FI1PjJ3MEi4
HeLa	NV\LdZpJU2mwYYPlJGF{e2G7	NX;yV3REOTBizszN	MVGxJIg>	MXjEUXNQ	NWDteotSUW6mdXPld{BRSVKSIHPs[YF3[WenIHL5JIlvcGmkaYTpcocheHKxc3Xhd49u\SCjY4Tpeol1gQ>?	MUSyOFMzOTh\|Mx?=
MDA-MB-231	MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV2xJO69VQ>?	NYTHVmtoPzJiaB?=	NXv3O\|Z2TE2VTx?=	NX;BcZZjUUN3ME2wMlE5KM7:TR?=	M3ftNVI1OTV\|MkC2
MCF-7	M1m2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXFNUDPxE1?	NVzYUpNTPzJiaB?=	M4[5VmROW09?	M2[yWmlEPTB;MD6xN{DPxE1?	NGnaXHMzPDF3M{KwOi=>
MCF10A	NEW0TWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLqNUDPxE1?	MlvKO\|IhcA>?	NUHiUGltTE2VTx?=	MnTpTWM2OD1yLkK5JO69VQ>?	NHy5W5ozPDF3M{KwOi=>
HEK-293	MYfLbY5ie2ViQYPzZZk>	NE\qU5YzKGGwZDCyNEDPxE1?	NUC1PI1TOiCq	NVrrRmJqTE2VTx?=	M1\5[WlvcGmkaYTzJGNpXC2OIHHjeIl3cXS7IIfpeIghUUN3MDDv[kA6KG6PIB?=	NHvBboYzOzV2MEe5NC=>
Calu6	MluzSpVv[3Srb36gRZN{[Xl?	NHfT[XQyOCEQvF2=	M1H4VlE5KGh?	NY\CRlRmTE2VTx?=	NIK2R4hUcWewaX\pZ4FvfGy7IHHjZ5VufWyjdHXzJIZz[XSjeHnuJJBz\WO3coPvdi=>	MY[yN\|UxPjR6Nh?=
IFN-gamma-induced RAW264.7	MofzSpVv[3Srb36gRZN{[Xl?			Mo\lSG1UVw>?	MWTJcohq[mm2czDubZRzcWNib4jp[IUheHKxZIXjeIlwdiC5aYToJGlEPTBib3[gNE4xPzdizszN	MYqyNlI4PzJ5Nx?=
IPC227F	MmLNR5l1d3SxeHnjJGF{e2G7	M1nxeVEh\|ryP	MlfoOFghcA>?	NEW3dWVFVVOR	MnztTWM2OD1yLkC3O{DPxE1?	MmrHNlE6OjR3Mki=
Hepa-1c1c7	MV;GeY5kfGmxbjDBd5NigQ>?	NX:wepprOjVizszN	NHrRbY83KGh?	M3H0SWROW09?	M2G3[Wlv[3KnYYPld{BPemZ{IIDyc5RmcW5ibHX2[Yw>	M13Yc\|IxOzl{NUS0
COS-7	M{PLcWN6fG:2b4jpZ{BCe3OjeR?=	NGjTS2YyOCEQvF2=		M2rJ[WROW09?	NY\TcGpwUUN3MEyxNEDPxE1?	M3X4T\|E5ODh6MEm3
HuH-7	MkGyR5l1d3SxeHnjJGF{e2G7	MWexNEDPxE1?		MUjEUXNQ	MkfBTWM2ODxzMDFOwG0>	MoP4NVgxQDhyOUe=
OCI-Ly3	MorUSpVv[3Srb36gRZN{[Xl?	MoPuNVAh\|ryPwrC=	MU[0JIg>	M1XycWROW09?	NV;wOIRrUW6mdXPld{BpfW2jbjDJb4FxeGGEYXzwbIEhe3SjYnnsbZpifGmxbjD3bZRpKEWFNUCgc4YhOSEQvF2=	MkDSNVgxOjRzMUO=
A2780 cDDP	MV\BdI9xfG:\|aYOgRZN{[Xl?		NF\Kc\|IzPCCq	M2fMc2ROW09?	M2S5Wmlv\HWlZYOgZZBweHSxc3nzJIJ6KGmwaHnibZRqdmdiUGTFUkBl\We{YXTheIlwdg>?	MX6xO\|Y5PDBzOB?=
LPS-stimulated RAW264.7 cells	MmTLSpVv[3Srb36gRZN{[Xl?			NEf5fVhFVVOR	MYrJcohq[mm2czDOSk1s[XCyYVKgSG5CKGKrbnTpcoc>	M{H1e\|E4PDB5Mke3
PC12	NF;rV5ZHfW6ldHnvckBCe3OjeR?=	NYrXcZZ[OTByIN88UeKh	MoPpNlQhcA>?	MVXEUXNQ	M3vpSWlvcGmkaYTzJFYuV0iGQT2gZY5lKEh{T{KtbY5lfWOnZDDjfZRwfG:6aXPpeJk>	NIP5O3gyPzF3OES1OC=>
PC3	NYfKPGc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUCyNEDPxE1?	NVPnO5JzPDhiaB?=	MoLBSG1UVw>?	NG\LfWtKSzVyPUCuOkDPxE1?	Ml\oNVY3QDZ3M{e=
LP-1	NUHZfYZjSXCxcITvd4l{KEG\|c3H5	NVLk[IxVOzByIH7N	M3fnS\|I1KGh?	NYLXeoNlTE2VTx?=	NWPkR\|BDUW6mdXPld{BieG:ydH;zbZMh[nliaX7jdoVie2mwZzDjcIVifmWmIGDBVnAhdGW4ZXygZY5lKHKnZIXjbY5oKE2lbD2xJJBzd3SnaX6gcIV3\Wx?	NXv6OXRTOTV7NUi1PFk>
ES6	NFmzTXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGrFTJRKSzVyPUCuNFE{ODZizszN	NXfYZldYW0GQR1XS
A101D	NGG4SINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTBwMEOyO\|kh\|ryP	NUe4NYk5W0GQR1XS
OCUB-M	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\UbpVKSzVyPUCuNFM4OzdizszN	MX;TRW5ITVJ?
LB2518-MEL	NWn5Uo5lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTBwMEO3OkDPxE1?	MWjTRW5ITVJ?
SH-4	NY[zdoNvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTBwMESzNUDPxE1?	M4r1R3NCVkeHUh?=
KNS-42	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX:4RXkzUUN3ME2wMlA1PDRzIN88US=>	MoLoV2FPT0WU
DSH1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIG0NlRKSzVyPUCuNFUzQDlizszN	NIT1VXBUSU6JRWK=
NTERA-S-cl-D1	MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1i5NWlEPTB;MD6wOVc4OiEQvF2=	NX3ncYdLW0GQR1XS
D-542MG	NFvHOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPmTWM2OD1yLkC1PVU4KM7:TR?=	MlW5V2FPT0WU
KS-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfk[WVKSzVyPUCuNFY1PThizszN	NE[yT2pUSU6JRWK=
BL-41	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfneYdKSzVyPUCuNFY6PDdizszN	NGHaNpNUSU6JRWK=
LXF-289	NEG5bpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLsPGtSUUN3ME2wMlA4ODZ4IN88US=>	M4LKVXNCVkeHUh?=
D-247MG	M1\mfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTBwMEeyNFkh\|ryP	NX3xeFZLW0GQR1XS
MMAC-SF	M2\sdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7TTWM2OD1yLkC3NlY5KM7:TR?=	MUTTRW5ITVJ?
CP66-MEL	M17Y[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXabmhKSzVyPUCuNFc2KM7:TR?=	MkjTV2FPT0WU
LB771-HNC	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jSSmlEPTB;MD6wPFA{PiEQvF2=	M2f1XXNCVkeHUh?=
no-10	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnkTWM2OD1yLkC4PVA6KM7:TR?=	MXvTRW5ITVJ?
A388	NVfzeIVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTBwMEmwOlUh\|ryP	NXnSTWJwW0GQR1XS
OPM-2	NGjMXIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3r2cWlEPTB;MD6xNFQ4PCEQvF2=	NGHuWYZUSU6JRWK=
OVCAR-4	MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPKS\|A5UUN3ME2wMlExQTN6IN88US=>	NWT4cGN1W0GQR1XS
HOP-62	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrxS2NHUUN3ME2wMlExQTR7IN88US=>	MWfTRW5ITVJ?
ML-2	NWDE[Y1yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEXTVFNKSzVyPUCuNVE5ODZizszN	MVXTRW5ITVJ?
UACC-257	NHHv[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnG4TWM2OD1yLkGxPVI4KM7:TR?=	MkXEV2FPT0WU
NEC8	MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH[3SmlKSzVyPUCuNVE6QTVizszN	Mo\0V2FPT0WU
ONS-76	M{PjbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3qTWM2OD1yLkGyPVM2KM7:TR?=	MmW4V2FPT0WU
KE-37	NGDuTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfCOm9KSzVyPUCuNVMzPzhizszN	NFW3dVNUSU6JRWK=
HT-144	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fmNmlEPTB;MD6xN\|g6PSEQvF2=	M33odHNCVkeHUh?=
LB2241-RCC	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjBS\|JKSzVyPUCuNVQzPDdizszN	NGHXdXlUSU6JRWK=
TE-5	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTBwMUSyO\|gh\|ryP	NXnxV\|JjW0GQR1XS
KINGS-1	NX;heYdRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\jTWlEPTB;MD6xOFc6KM7:TR?=	NXPJ[IhQW0GQR1XS
NCI-H69	MnPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVX1R45QUUN3ME2wMlE2OTRzIN88US=>	Mn;RV2FPT0WU
CAS-1	Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnz3TWM2OD1yLkG1OFgzKM7:TR?=	M{P0bnNCVkeHUh?=
D-263MG	MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTBwMU[wNFYh\|ryP	M4DwXXNCVkeHUh?=
A253	NGLs[YhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTYTWM2OD1yLkG2NVI5KM7:TR?=	NWrBboZHW0GQR1XS
PF-382	NVXYN3ZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fRNmlEPTB;MD6xOlcxPiEQvF2=	M{XMOXNCVkeHUh?=
CESS	NEHmcVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTBwMUewOkDPxE1?	MY\TRW5ITVJ?
MZ2-MEL	MlzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTETWM2OD1yLkG3OVU6KM7:TR?=	NXvGW4xuW0GQR1XS
HEL	NYq4[nY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\RTWM2OD1yLkG4OVE4KM7:TR?=	MWLTRW5ITVJ?
D-392MG	NYnYO\|g5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlywTWM2OD1yLkG5NVE2KM7:TR?=	NI[1fWhUSU6JRWK=
SK-LMS-1	NHLkUJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\zOW9KSzVyPUCuNVk{ODNizszN	MkTBV2FPT0WU
GI-ME-N	NWC0[2w{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3PxWGlEPTB;MD6xPVMxPiEQvF2=	MUXTRW5ITVJ?
LB831-BLC	NXOxUG9RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfVTWM2OD1yLkG5N\|Qh\|ryP	NY[xRo01W0GQR1XS
DU-4475	NEe4XlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF64fGtKSzVyPUCuNVk3PThizszN	NYjOe4Y1W0GQR1XS
IST-SL1	NX\WeJVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTBwMkCwPVQh\|ryP	NFWx[XZUSU6JRWK=
GAK	NF7iR\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3W5T2lEPTB;MD6yNFU{PCEQvF2=	MYnTRW5ITVJ?
EW-1	Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjG[2JOUUN3ME2wMlIyODR5IN88US=>	MkXSV2FPT0WU
LAMA-84	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrhTWM2OD1yLkKxPFUyKM7:TR?=	NIHmbGtUSU6JRWK=
SK-UT-1	M{G2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXPseWh4UUN3ME2wMlIzODR7IN88US=>	M4rQRXNCVkeHUh?=
VA-ES-BJ	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTBwMkKyOVch\|ryP	NHfrU2JUSU6JRWK=
ACN	NX7He4tmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTBwMkK2N\|gh\|ryP	MkWwV2FPT0WU
SK-PN-DW	NEfWOnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTBwMkOxPUDPxE1?	NGPLO3RUSU6JRWK=
HD-MY-Z	M2nnWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLYRoNrUUN3ME2wMlI{OzB\|IN88US=>	NWPVWm51W0GQR1XS
LB373-MEL-D	NWrS[W02T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLVdGFJUUN3ME2wMlI1OTl6IN88US=>	M3TK[3NCVkeHUh?=
COLO-829	NVficVdvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPObGhKSzVyPUCuNlQzPTdizszN	M1vlZnNCVkeHUh?=
ES8	NHjWdmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M36w[mlEPTB;MD6yOFc3OyEQvF2=	MWrTRW5ITVJ?
RXF393	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3j2c2lEPTB;MD6yOVAyPSEQvF2=	NVftZlFGW0GQR1XS
TK10	M{X0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTBwMkW0N\|Uh\|ryP	NFTWfm1USU6JRWK=
LOUCY	M4XTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXlS2pKSzVyPUCuNlU1PTZizszN	NGfPUVJUSU6JRWK=
MZ7-mel	MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHhboFxUUN3ME2wMlI3Ozd2IN88US=>	M13xZ3NCVkeHUh?=
CP67-MEL	M4rwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTBwMk[3N{DPxE1?	NETSW5BUSU6JRWK=
C2BBe1	NG\LUoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nUZWlEPTB;MD6yO\|kxPyEQvF2=	MnnzV2FPT0WU
K052	Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm[zTWM2OD1yLkK4PVkh\|ryP	M4jjbnNCVkeHUh?=
MOLT-16	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmG5TWM2OD1yLkK5OVI1KM7:TR?=	MX3TRW5ITVJ?
KNS-81-FD	NUDSbm9YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlmwTWM2OD1yLkOwN\|I{KM7:TR?=	M4jYRXNCVkeHUh?=
CMK	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rvc2lEPTB;MD6zNVEzKM7:TR?=	M2LOR3NCVkeHUh?=
LAN-6	NWTJeW1RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\HN\|JKSzVyPUCuN\|E{KM7:TR?=	NF;GbFZUSU6JRWK=
KLE	NYfjb3dST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHwVJpKSzVyPUCuN\|E{ODZizszN	M2PG[HNCVkeHUh?=
NCCIT	NX\RSmR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TQbmlEPTB;MD6zNVc5OyEQvF2=	NF[0PIVUSU6JRWK=
HH	NVLDN\|E1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\nV5BjUUN3ME2wMlMzQDl5IN88US=>	M3f2TnNCVkeHUh?=
TE-8	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTBwM{SyO\|kh\|ryP	NGT5fndUSU6JRWK=
GDM-1	NVzvVJJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jxb2lEPTB;MD6zOVExPCEQvF2=	MkjjV2FPT0WU
NCI-H747	NVXm[mY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\XTWM2OD1yLkO3NVA{KM7:TR?=	NYiyfnJjW0GQR1XS
NCI-H1092	M1;wVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTBwM{i4OFQh\|ryP	MVzTRW5ITVJ?
8-MG-BA	MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTBwM{m4N\|ch\|ryP	NHHMVFFUSU6JRWK=
NB17	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTBwNEK5O{DPxE1?	NUDmR29xW0GQR1XS
LC4-1	M3PyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfhVHFKUUN3ME2wMlQ{PjB5IN88US=>	Mn61V2FPT0WU
TE-1	M4DoOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\OXoVKSzVyPUCuOFUyOTlizszN	NVnVeVNmW0GQR1XS
KALS-1	MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIP0UHlKSzVyPUCuOFY2QDRizszN	M2T2SnNCVkeHUh?=
CCRF-CEM	MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2nTO2lEPTB;MD60O\|Y4PCEQvF2=	NUP2UIdRW0GQR1XS
OS-RC-2	Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPZXlRKSzVyPUCuOFc6PzJizszN	NVfOe45zW0GQR1XS
A704	MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPSW5FKSzVyPUCuOFg3QTJizszN	MmXzV2FPT0WU
BB49-HNC	MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DUcWlEPTB;MD60PVA6PiEQvF2=	MmHqV2FPT0WU
EVSA-T	MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3q0V2lEPTB;MD60PVkyOSEQvF2=	NVf3VWFmW0GQR1XS
Mo-T	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTBwNUG3OlIh\|ryP	Mly0V2FPT0WU
MONO-MAC-6	NELnb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXSTWM2OD1yLkWzOlEyKM7:TR?=	NEXuV2dUSU6JRWK=
BB65-RCC	NFnBVW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zNZWlEPTB;MD61OlgyOSEQvF2=	M{TyVXNCVkeHUh?=
NCI-H1882	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HaTmlEPTB;MD61PVA{PiEQvF2=	NFHteGlUSU6JRWK=
TE-9	NUPP[WpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\wVGlEPTB;MD62NVA{OyEQvF2=	NFe5WZZUSU6JRWK=
NCI-H2126	M2r0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTBwNkK2Olkh\|ryP	MmrQV2FPT0WU
SF268	M3OzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTBwNkW2OFEh\|ryP	MWrTRW5ITVJ?
SW872	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTBwNkW3Nlkh\|ryP	MlHFV2FPT0WU
LS-513	NYXjPJp1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTBwNk[3OVEh\|ryP	NFLETVVUSU6JRWK=
NCI-H1355	NUjq[pZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPBdmRKSzVyPUCuOlg3OTlizszN	NWO1TIhxW0GQR1XS
BL-70	MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTBwNkmzPFgh\|ryP	NGHaTZdUSU6JRWK=
NCI-SNU-5	NIf6[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\QfGlEPTB;MD62PVU1PSEQvF2=	MUDTRW5ITVJ?
SNU-C2B	NEHtSnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlqyTWM2OD1yLkewO\|M6KM7:TR?=	NUTEfYh1W0GQR1XS
GB-1	Mnm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTZTWM2OD1yLkeyNVI1KM7:TR?=	NGLGSJlUSU6JRWK=
CTB-1	MmfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\Ub3pKSzVyPUCuO\|c6PTVizszN	NV\RenB[W0GQR1XS
Becker	NUH3dXlYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnH[JpQUUN3ME2wMlc6PjJzIN88US=>	M1HTS3NCVkeHUh?=
KM12	M4HScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTBwOEW0OlYh\|ryP	NWrkSHBIW0GQR1XS
ES7	MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvUTWM2OD1yLki5OlUh\|ryP	NGjjeY1USU6JRWK=
COLO-684	M{WxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDZTWM2OD1yLkmwOlU5KM7:TR?=	MmHDV2FPT0WU
HCC2998	NUPTZ2VFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3O1WWlEPTB;MD65N\|g2PCEQvF2=	MXLTRW5ITVJ?
TE-10	NGq0UG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknjTWM2OD1yLkm2OFMh\|ryP	MWnTRW5ITVJ?
SF126	M4LoWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTu[oVQUUN3ME2wMlk5QTdzIN88US=>	MVLTRW5ITVJ?
EKVX	M1;Wemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDlTWM2OD1zLkCzOFQzKM7:TR?=	NHXFSolUSU6JRWK=
KARPAS-45	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nvdGlEPTB;MT6wOFAyPiEQvF2=	MnHnV2FPT0WU
KGN	NUO2d4hoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTFwMEWwOFUh\|ryP	MUHTRW5ITVJ?
ES1	NGrOTYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfKN3VKSzVyPUGuNFc6OjFizszN	MkLHV2FPT0WU
L-540	MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PKSGlEPTB;MT6xNVg{QSEQvF2=	MlnEV2FPT0WU
KURAMOCHI	MorVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jZTGlEPTB;MT6xNlM4PCEQvF2=	NYPZSm9PW0GQR1XS
LU-65	M1n6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvCN25EUUN3ME2xMlEzPzV\|IN88US=>	NYDKT2dtW0GQR1XS
MFH-ino	NEDiSYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPHTWM2OD1zLkG3OVAyKM7:TR?=	NELN[2dUSU6JRWK=
NCI-H23	M{TMdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoGyTWM2OD1zLkKwOFEh\|ryP	M1X6RnNCVkeHUh?=
IA-LM	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTFwMkSxNVYh\|ryP	Mkj5V2FPT0WU
PSN1	MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnidVJCUUN3ME2xMlI4ODF4IN88US=>	NVnYV5R7W0GQR1XS
NCI-H719	MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7ETWM2OD1zLkK3OFEyKM7:TR?=	M2HqdnNCVkeHUh?=
SW684	Ml:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2nje2lEPTB;MT6yPFY2QSEQvF2=	NHHU[GFUSU6JRWK=
HCE-4	NH3FSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTFwM{CyNlEh\|ryP	MlXSV2FPT0WU
EW-16	NUjxNGxzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTFwM{GzOFch\|ryP	NUPpdJpSW0GQR1XS
NCI-H128	NUHGOHJIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDSTWM2OD1zLkO1PFE1KM7:TR?=	NG\jWWNUSU6JRWK=
HC-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1W1fGlEPTB;MT6zPFE4KM7:TR?=	M3TpcXNCVkeHUh?=
IST-MES1	NGTJTXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7NTWM2OD1zLkSwNlA5KM7:TR?=	Mof4V2FPT0WU
Raji	MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTFwNEG4OUDPxE1?	NIHSdYlUSU6JRWK=
DMS-114	M1y5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTFwNES1N\|kh\|ryP	M3q5c3NCVkeHUh?=
GI-1	NHTEcpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfmSpNjUUN3ME2xMlQ4OTNzIN88US=>	NHLCeXVUSU6JRWK=
NCI-H2081	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLq[ZBNUUN3ME2xMlU2OTl4IN88US=>	NXXjOFlLW0GQR1XS
LC-1F	NV[0[otrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vRdmlEPTB;MT61OVE6QCEQvF2=	M2j4XnNCVkeHUh?=
NCI-H2227	M4K2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYi1bXY5UUN3ME2xMlYyPTZzIN88US=>	M2O1RXNCVkeHUh?=
D-502MG	NYfFZYdpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\nW5VKSzVyPUGuOlczOTFizszN	Mof1V2FPT0WU
NCI-H2141	NWLQc41pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXjR2NKSzVyPUGuOlc{OTdizszN	M134OXNCVkeHUh?=
LS-411N	M1TEb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHKNGNKSzVyPUGuOlk5ODdizszN	NIrGd4tUSU6JRWK=
SU-DHL-1	M4DTWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfX[IhKSzVyPUGuO\|EzQDFizszN	NWfxeFBMW0GQR1XS
BB30-HNC	M2nlV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7QTWM2OD1zLkeyOlg2KM7:TR?=	NXLZdFhyW0GQR1XS
TE-15	Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTFwOUKzO\|Mh\|ryP	MUHTRW5ITVJ?
JVM-3	NHPlNIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnz6TWM2OD1zLkmzPVA1KM7:TR?=	NGLvWVBUSU6JRWK=
IST-SL2	MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmrDTWM2OD1{LkCxNlUzKM7:TR?=	Mny3V2FPT0WU
EW-18	MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfJ[Y5KSzVyPUKuNFI{OzdizszN	MWjTRW5ITVJ?
DJM-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTJwMEK1OVIh\|ryP	MoPMV2FPT0WU
no-11	NVHNdZdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Moq5TWM2OD1{LkCzNVA1KM7:TR?=	MlX5V2FPT0WU
QIMR-WIL	NFHHfm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M36yRmlEPTB;Mj6xOlc3OiEQvF2=	NYKzZ5JTW0GQR1XS
MC-CAR	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTJwMkK5OUDPxE1?	M4HEOXNCVkeHUh?=
KM-H2	NIDkcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHkTWM2OD1{LkK5NFQ{KM7:TR?=	NV:5PZhnW0GQR1XS
ECC12	NFXIbYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4flNmlEPTB;Mj6zO\|k1KM7:TR?=	NGXWTZFUSU6JRWK=
HCE-T	M2jnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTJwNES4PFMh\|ryP	NIS4SFBUSU6JRWK=
MFM-223	M2H6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PmbWlEPTB;Mj61NFg4OSEQvF2=	NGD5NYpUSU6JRWK=
SW982	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIrKZ2dKSzVyPUKuOVE1QCEQvF2=	M3TaOXNCVkeHUh?=
KG-1	M2nm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHuTWM2OD1{Lki4O\|kyKM7:TR?=	NU\qT3RiW0GQR1XS
ES4	M3X1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTNwME[xNVEh\|ryP	MX\TRW5ITVJ?
SCC-3	MofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHCTIN6UUN3ME2zMlExQDR6IN88US=>	M2\XW3NCVkeHUh?=
RH-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTNwM{i3OFgh\|ryP	Mmj4V2FPT0WU
NCI-H748	NILNNoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1u1NWlEPTB;Mz60OFI3PiEQvF2=	MkHjV2FPT0WU
HCC2218	NEHyd2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mle2TWM2OD1\|LkS2PVM4KM7:TR?=	MkXqV2FPT0WU
MEG-01	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEK4W3BKSzVyPUOuOVk3QCEQvF2=	M4DzRXNCVkeHUh?=
NB12	Mme1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTNwNUm4PFgh\|ryP	Ml\wV2FPT0WU
SNB75	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHi3T\|FKSzVyPUOuOlAyODNizszN	M1O4RnNCVkeHUh?=
KMS-12-PE	MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfGTWM2OD1\|Lk[3O\|I{KM7:TR?=	M{PMNnNCVkeHUh?=
SKM-1	NFnCVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF;Bb45KSzVyPUOuO\|E{PzZizszN	NX\Dc3JiW0GQR1XS
COLO-320-HSR	NUjoZYJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfiXmxJUUN3ME2zMlc2PjN2IN88US=>	MWTTRW5ITVJ?
NKM-1	NXjCemdET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjxTJRKSzVyPUOuO\|c{PzhizszN	NH\2V\|FUSU6JRWK=
TE-6	NUjVfFJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rZS2lEPTB;Mz65OFU3OSEQvF2=	NXrlZlM2W0GQR1XS
D-336MG	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnm4TWM2OD12LkCxNVY3KM7:TR?=	NE\GXXlUSU6JRWK=
NCI-H1650	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rnR2lEPTB;ND6xOVc6PyEQvF2=	NUTISVFNW0GQR1XS
ES3	M2myO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfjWXBKSzVyPUSuN\|I5OjRizszN	M2LldXNCVkeHUh?=
YT	MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmGzTWM2OD12LkO1OFI1KM7:TR?=	NXj1d5ZQW0GQR1XS
ES5	MoHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrseJJKSzVyPUSuOFAzPTVizszN	NVjHfXF7W0GQR1XS
LB647-SCLC	M4\yWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTRwNU[zNFgh\|ryP	MYrTRW5ITVJ?
HAL-01	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH71R4FKSzVyPUSuOVcxOzRizszN	MX7TRW5ITVJ?
LP-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTRwN{KzO\|Eh\|ryP	MnrmV2FPT0WU
BC-1	NEfIe4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TwUWlEPTB;NT6wNFQ1PyEQvF2=	Mn:zV2FPT0WU
EB-3	MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3[0NGlEPTB;NT6wN\|A1OSEQvF2=	MWPTRW5ITVJ?
GT3TKB	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGezV3pKSzVyPUWuNVc3PjJizszN	MkfEV2FPT0WU
NCI-H209	NILXSphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml36TWM2OD13LkG5N\|UzKM7:TR?=	MVnTRW5ITVJ?
BT-474	MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PrVWlEPTB;NT6yN\|ExOiEQvF2=	MXnTRW5ITVJ?
RKO	NHzpXmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37C[WlEPTB;NT6yN\|QzOiEQvF2=	NXnw[ZJIW0GQR1XS
SIMA	M3fnTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3mcodKSzVyPUWuN\|A4PjVizszN	MX;TRW5ITVJ?
RL	NUjBeYh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTVwM{e1OFEh\|ryP	MkjOV2FPT0WU
GCIY	NED5PYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTVwNEeyN\|Yh\|ryP	MUHTRW5ITVJ?
Calu-6	M2myfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIK2UYVKSzVyPUWuOlIzKM7:TR?=	M3XWZnNCVkeHUh?=
ALL-PO	NVnL[VdIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTVwNkO3PVUh\|ryP	MUPTRW5ITVJ?
ARH-77	NFG3WpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTVwNkewPFch\|ryP	MlrpV2FPT0WU
A4-Fuk	NEPxVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\VOFl4UUN3ME22MlA5OTF6IN88US=>	M3e5S3NCVkeHUh?=
NCI-H1581	MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljoTWM2OD14LkKzPFQ6KM7:TR?=	Mly0V2FPT0WU
HUTU-80	M1TwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MormTWM2OD14LkO2PFk4KM7:TR?=	MoezV2FPT0WU
TGW	NVq1VVQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjp[GtVUUN3ME22MlQ2PTl\|IN88US=>	NW[xUlB{W0GQR1XS
SK-N-FI	M3LzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;FPVdKSzVyPU[uOFU5PTRizszN	Mlv0V2FPT0WU
U-266	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYKzSZN{UUN3ME22MlUyQTJ4IN88US=>	M3uzZnNCVkeHUh?=
EM-2	NVXSfoltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTZwNkewPVkh\|ryP	NGLVUIFUSU6JRWK=
NMC-G1	NX3CRYNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTqUldKSzVyPU[uO\|E5QTVizszN	NWroe5NoW0GQR1XS
KASUMI-1	M3rEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jBUWlEPTB;Nj64OFc5PyEQvF2=	MUTTRW5ITVJ?
NALM-6	NGH3RlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;UWXR[UUN3ME22Mlg3PzV2IN88US=>	NVz5T2toW0GQR1XS
OCI-AML2	NXH3epJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTdwMECzNlYh\|ryP	NH;oVVJUSU6JRWK=
SHP-77	M3K5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXXR3NFUUN3ME23MlIzPDNizszN	MWfTRW5ITVJ?
NOMO-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7BcZFKSzVyPUeuNlQzPTRizszN	NWrZe2dOW0GQR1XS
SK-N-DZ	M1fGc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjl[lRKSzVyPUeuO\|ExQDlizszN	NWXSO21NW0GQR1XS
LB1047-RCC	NGTpeXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEW5ZYtKSzVyPUeuO\|IzOzFizszN	NX\2fGV{W0GQR1XS
MZ1-PC	MkDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HrTWlEPTB;Nz64OlU2QCEQvF2=	M3PQ[XNCVkeHUh?=
NB10	NGG1T5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTdwOUm1OVYh\|ryP	NUm3bG5lW0GQR1XS
RL95-2	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7DV3ZKSzVyPUiuNVA5PDJizszN	NYD5Zm5bW0GQR1XS
OMC-1	MlzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLaTWM2OD16LkWyNVkyKM7:TR?=	NFnmVIhUSU6JRWK=
D-283MED	NGm3bGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XrcGlEPTB;OD65NVcyQSEQvF2=	M12ydXNCVkeHUh?=
MC116	MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHf5PWZKSzVyPUiuPVc6PCEQvF2=	MkDVV2FPT0WU
SJSA-1	NYXUUWRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7vUmNKSzVyPUmuNFkxQTFizszN	Ml;1V2FPT0WU
JiyoyeP-2003	MoH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfCXYdXUUN3ME25MlI6OzF5IN88US=>	Mkn5V2FPT0WU
IST-MEL1	NV;kcXhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTlwN{SxPVgh\|ryP	M37HOXNCVkeHUh?=
CTV-1	M1e5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTJemtKSzVyPUGwMlA6PzlizszN	Mn63V2FPT0WU
NH-12	M3ftZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFH0OVdKSzVyPUGwMlI1OzNizszN	Mon6V2FPT0WU
CA46	M1XLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHuxNmdKSzVyPUGwMlM3OSEQvF2=	MULTRW5ITVJ?
NCI-SNU-1	MlvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1O1cmlEPTB;MUCuOFk3QSEQvF2=	NGDj[GlUSU6JRWK=
SCLC-21H	NHnjNXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTFyLk[1PVYh\|ryP	M37JdHNCVkeHUh?=
EC-GI-10	MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnzXVdHUUN3ME2xNE44ODNzIN88US=>	NWj0XZl5W0GQR1XS
SR	NWjTd2JST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTFzLkCxPFUh\|ryP	M{exOnNCVkeHUh?=
NCI-H1648	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUOwRYNTUUN3ME2xNU4xQTZ3IN88US=>	Mkm3V2FPT0WU
TGBC1TKB	MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXzUpJ1UUN3ME2xNU41OTB{IN88US=>	NVTGemhuW0GQR1XS
EW-11	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1ywbmlEPTB;MUGuOVE5PiEQvF2=	NFXsV2VUSU6JRWK=
SK-MM-2	NIXGSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLZ[lVKSzVyPUGxMlgxPjFizszN	NXHsNJBbW0GQR1XS
NCI-H524	NGS4TXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn65TWM2OD1zMT65PFIzKM7:TR?=	Ml7DV2FPT0WU
NOS-1	NYjzeWxsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4TMUGlEPTB;MUKuNFM1PSEQvF2=	MUHTRW5ITVJ?
AM-38	MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLKTWM2OD1zMj61OlM{KM7:TR?=	M12zfXNCVkeHUh?=
A498	NE[5UFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXv1elBUUUN3ME2xNk44ODZ7IN88US=>	MorGV2FPT0WU
KARPAS-422	NYL0NGFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXBTWM2OD1zMj63OFk3KM7:TR?=	NVrnc4FEW0GQR1XS
LU-139	NHPYeHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTF{LkmwNlYh\|ryP	MV\TRW5ITVJ?
COR-L88	NGTmNIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nndmlEPTB;MUKuPVM5OiEQvF2=	MkjKV2FPT0WU
K5	NVHVdVhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37HVGlEPTB;MUKuPVQ3OiEQvF2=	M4frT3NCVkeHUh?=
NB13	M4jLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PMU2lEPTB;MUKuPVc5OyEQvF2=	MYDTRW5ITVJ?
MRK-nu-1	NFPZc4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrYTWM2OD1zMz6xPVUh\|ryP	MV3TRW5ITVJ?
MHH-NB-11	NFj0dGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYruO\|FSUUN3ME2xN{4zQTB{IN88US=>	NV[zc3hVW0GQR1XS
KU812	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIW0fXNKSzVyPUGzMlYyOjRizszN	NXzsd3hJW0GQR1XS
TE-12	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;KTWM2OD1zMz62PVk1KM7:TR?=	MUnTRW5ITVJ?
NCI-N87	NWHRemNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDXWVI1UUN3ME2xN{44OzZizszN	NIf2[FFUSU6JRWK=
EB2	NHLMPI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIO3dGVKSzVyPUGzMlg2ODVizszN	Mmn5V2FPT0WU
DB	M{Xw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MneyTWM2OD1zMz65PFg2KM7:TR?=	MX3TRW5ITVJ?
697	NGq1NYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTF2LkS1NVEh\|ryP	NGjMbpRUSU6JRWK=
MSTO-211H	M{TlWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInrfW5KSzVyPUG0Mlc1PDhizszN	MUDTRW5ITVJ?
JVM-2	NETQdXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HuOWlEPTB;MUSuO\|c{PSEQvF2=	Mnm1V2FPT0WU
COLO-824	M2XIfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1GwUWlEPTB;MUSuO\|k6PCEQvF2=	MVnTRW5ITVJ?
BC-3	MmDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUj1S3ppUUN3ME2xOU4{QThizszN	Mn3yV2FPT0WU
BOKU	NVyxNlFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTF3Lkm2NFgh\|ryP	NXTXZZZ7W0GQR1XS
GOTO	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTF4Lkm2NVch\|ryP	M1P1OHNCVkeHUh?=
HCC2157	NXPlUpRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HKWmlEPTB;MUeuOFc2PSEQvF2=	NF\lNohUSU6JRWK=
LS-1034	MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4G3OGlEPTB;MUeuOlgyQCEQvF2=	NGPQc41USU6JRWK=
CAL-148	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\lTWM2OD1zNz65O\|k3KM7:TR?=	NEK3SoNUSU6JRWK=
MOLT-4	NUHvO4ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlS4TWM2OD1zOD64NlA5KM7:TR?=	MXrTRW5ITVJ?
Daudi	MmTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33lOWlEPTB;MUiuPVI{OSEQvF2=	M2\RZXNCVkeHUh?=
J-RT3-T3-5	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTF7LkSwOlYh\|ryP	MmOyV2FPT0WU
KMOE-2	NVfRXlFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojhTWM2OD1zOT62OFgzKM7:TR?=	NWTpT4NmW0GQR1XS
HL-60	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWD0TGhsUUN3ME2yNE4yQTZ3IN88US=>	M2D6UnNCVkeHUh?=
P31-FUJ	NEW2cpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTJyLkS3OVMh\|ryP	NVXocohjW0GQR1XS
IM-9	M3;3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjLelVOUUN3ME2yNE43OjJ2IN88US=>	NGnIfopUSU6JRWK=
HDLM-2	NUXyVYR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILvfoFKSzVyPUKwMlg5OjFizszN	MnHHV2FPT0WU
NCI-H1304	NGnkcnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfvdWZUUUN3ME2yNU4xOzFzIN88US=>	NFvkZYVUSU6JRWK=
NCI-H345	Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfUTWM2OD1{MT6wOlQ{KM7:TR?=	NVnPRmhPW0GQR1XS
RPMI-6666	NIm3dXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjK[HA2UUN3ME2yNU4{PjB{IN88US=>	NH;vT3VUSU6JRWK=
GR-ST	NHLt[HlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknyTWM2OD1{MT60NVch\|ryP	MUPTRW5ITVJ?
CHP-126	NICxdWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTJzLk[xPFEh\|ryP	M3XpNHNCVkeHUh?=
EHEB	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPIUmJIUUN3ME2yNU43PzNzIN88US=>	M4jKRXNCVkeHUh?=
CPC-N	MonDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHH0NnpKSzVyPUK0MlAzODFizszN	NWHUUVJRW0GQR1XS
NB1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTJ2Lk[5N\|kh\|ryP	MkPyV2FPT0WU
LS-123	NVLH[5I1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHLPVZKSzVyPUK0MlkxOTJizszN	NWjxPVdWW0GQR1XS
ST486	M4qxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnJXWtrUUN3ME2yOU4yOTF\|IN88US=>	NX;aRW06W0GQR1XS
NCI-H1963	MoCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTJ4LkC2NlMh\|ryP	MVvTRW5ITVJ?
U-87-MG	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mli2TWM2OD1{Nj63OlQ1KM7:TR?=	MWnTRW5ITVJ?
COR-L279	NHr2XFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTJ4Lke5NlIh\|ryP	MVXTRW5ITVJ?
LU-165	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXad\|JpUUN3ME2yPE4xQDZzIN88US=>	NGe2NGlUSU6JRWK=
COLO-800	M1fFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHS3b3ZKSzVyPUK4MlI6PTZizszN	NXe3ZZYxW0GQR1XS
ETK-1	NVO3W3ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETFNnRKSzVyPUK4MlM1PDZizszN	MlrBV2FPT0WU
LNCaP-Clone-FGC	NHHkS4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTJ7LkmyPFEh\|ryP	MVPTRW5ITVJ?
SIG-M5	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzoN5pKSzVyPUOwMlc6PTJizszN	M4nDXXNCVkeHUh?=
NB6	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\TT5NKUUN3ME2zNE46PTB\|IN88US=>	MXHTRW5ITVJ?
NCI-H2107	NXjRUmFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWL6XoE5UUN3ME2zNU4zOzN6IN88US=>	MVnTRW5ITVJ?
SNU-C1	NGnCcHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTaTWM2OD1\|MT6zNVI3KM7:TR?=	MVzTRW5ITVJ?
JAR	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7wfWRKSzVyPUOxMlM4QTlizszN	M4WxbnNCVkeHUh?=
L-363	MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIjXUI5KSzVyPUOyMlIyPDRizszN	NFq2W3lUSU6JRWK=
EW-24	M3TkXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;4bmlEPTB;M{KuN\|Q4PCEQvF2=	NGryW5ZUSU6JRWK=
NB69	MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3xTWM2OD1\|Mz62OFU1KM7:TR?=	NVPpOIpqW0GQR1XS
EW-13	MoX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPxUJFKSzVyPUOzMlg6PjlizszN	NUC0SJZIW0GQR1XS
Ramos-2G6-4C10	NWH4dZpVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrETWM2OD1\|ND6yPVk{KM7:TR?=	M2W1PHNCVkeHUh?=
TE-11	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTN2LkS4NlIh\|ryP	NUHYfWw4W0GQR1XS
L-428	MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTN2Lke1N\|Yh\|ryP	NFfDdXJUSU6JRWK=
KP-N-YN	NVLRSpc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTN2LkmwOVch\|ryP	Mn7GV2FPT0WU
CGTH-W-1	M4fXfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XHUmlEPTB;M{[uPVA1QCEQvF2=	MVHTRW5ITVJ?
K-562	MoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYKySJJoUUN3ME2zO{4xQDZ2IN88US=>	MVHTRW5ITVJ?
NCI-H1299	NHrPNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFG2bJlKSzVyPUO4MlE3ODNizszN	NXH4ZodLW0GQR1XS
RCC10RGB	MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3pdJZKSzVyPUO4MlIxQDNizszN	NXWyV3BwW0GQR1XS
NCI-SNU-16	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfpTWM2OD1\|OD61OlU{KM7:TR?=	MYTTRW5ITVJ?
LC-2-ad	NFjHOW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLBfVd{UUN3ME2zPU41OzN5IN88US=>	NG\qPFdUSU6JRWK=
MHH-PREB-1	NIXJPVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTN7LkezPFgh\|ryP	NUnTfHdIW0GQR1XS
NCI-H64	MnPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTRyLkC5OFgh\|ryP	M2Lyb3NCVkeHUh?=
LB996-RCC	NWfoVVV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH3ySGVKSzVyPUSwMlg4OTZizszN	NGLOcVRUSU6JRWK=
DEL	NGK3bXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEG4V4pKSzVyPUSxMlQ1ODVizszN	NHW3fG5USU6JRWK=
MLMA	Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTRzLke1PVUh\|ryP	NGH6WJpUSU6JRWK=
SBC-1	M3nwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrjbVRqUUN3ME20Nk4yQDB4IN88US=>	NGLxZWRUSU6JRWK=
MPP-89	M3LjNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTR{LkW4O\|Uh\|ryP	NXjvU4lFW0GQR1XS
MV-4-11	M33PeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTR{LkmwOlch\|ryP	MU\TRW5ITVJ?
EoL-1-	NVHhWHNvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{ixeWlEPTB;NESuNVU3QCEQvF2=	Mo\wV2FPT0WU
CW-2	M1fZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PMOmlEPTB;NESuPFM1OiEQvF2=	MkXuV2FPT0WU
HT	M3vEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fMN2lEPTB;NEWuO\|AxPyEQvF2=	MWDTRW5ITVJ?
SW954	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfEZmZKSzVyPUS3MlQyOjhizszN	M37GfHNCVkeHUh?=
A3-KAW	M3LvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvmcIRKSzVyPUS5MlgxPjFizszN	M2Di[3NCVkeHUh?=
TC-YIK	NUjCPZJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzzWVdkUUN3ME21NE4xOzZ\|IN88US=>	NHHRS5ZUSU6JRWK=
SW962	M1nnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHBfpdCUUN3ME21OE45OzV5IN88US=>	NUG0SnN5W0GQR1XS
KP-N-RT-BM-1	MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPQTWM2OD13Nj62OlM5KM7:TR?=	NX\mSmRUW0GQR1XS
NCI-H1395	M{DzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV:1d2h1UUN3ME21PE45OTd{IN88US=>	M3:3PXNCVkeHUh?=
RPMI-8402	M2L2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\QTWM2OD13OD65OVI3KM7:TR?=	NFHBb\|NUSU6JRWK=
SCH	NFnkbpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfMTWM2OD14MD65OlM5KM7:TR?=	NXnwVoxuW0GQR1XS
NCI-H2196	MlnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF70V4tKSzVyPU[xMlI{OSEQvF2=	NF\vbpNUSU6JRWK=
LOXIMVI	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\qeWlUUUN3ME22NU45OjZ4IN88US=>	M1;2XXNCVkeHUh?=
TGBC24TKB	M4C3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fSRmlEPTB;NkKuNVQ6OSEQvF2=	MnnMV2FPT0WU
SK-MEL-2	NG\nV3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TOe2lEPTB;NkOuPVg6OiEQvF2=	MUHTRW5ITVJ?
U-698-M	MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mkf2TWM2OD14OD61Olg4KM7:TR?=	M4TKcXNCVkeHUh?=
NCI-H1522	NE[3XlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4G3XWlEPTB;NkmuNFA1PyEQvF2=	M4PO[3NCVkeHUh?=
UACC-812	NGGzNpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfYTXZTUUN3ME22PU42OjB7IN88US=>	MXHTRW5ITVJ?
MHH-CALL-2	NX7kTpd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MniwTWM2OD15MD6wOkDPxE1?	NETC[IpUSU6JRWK=
NB5	NX3VflZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTJTWM2OD15MD6zOFY5KM7:TR?=	NEHQN2hUSU6JRWK=
KARPAS-299	NW[4RVluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLpWmtKSzVyPUewMlQ1PDdizszN	NFP6VYZUSU6JRWK=
NCI-H1694	NF71XY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTdzLkCzNkDPxE1?	M1jjS3NCVkeHUh?=
NCI-H82	NF\2WYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTTXG9KSzVyPUexMlk2ODdizszN	NFfzd29USU6JRWK=
SCC-15	NIrqTJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETsR3lKSzVyPUeyMlM1KM7:TR?=	NXy0coQzW0GQR1XS
NCI-H1436	NF3oTJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTd{Lke0OVYh\|ryP	NWf1cmZpW0GQR1XS
ATN-1	M3mwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTd2LkWwOUDPxE1?	NGjBPItUSU6JRWK=
RPMI-8866	NEPXTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfHNJBzUUN3ME23OE44PTB7IN88US=>	NGfsd3hUSU6JRWK=
HCC1599	NFO0VlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYX3TlBFUUN3ME23OE45PzN{IN88US=>	NIW5OW5USU6JRWK=
NCI-H1155	NHHVe3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFLlfHhKSzVyPUe0Mlk{PjdizszN	NF7UUGZUSU6JRWK=
DOHH-2	M1TnfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlm3TWM2OD15ND65OVE1KM7:TR?=	NVGxXphMW0GQR1XS
SK-NEP-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXS1V3VRUUN3ME23OU4xPzV2IN88US=>	NUPH[ppNW0GQR1XS
HCC1187	MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;ITWM2OD15Nz62NVIzKM7:TR?=	MXPTRW5ITVJ?
NCI-H322M	NHLsN4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M361UmlEPTB;N{iuN\|cxQSEQvF2=	NGrXS\|BUSU6JRWK=
NCI-H526	M2fFU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTd6LkW4O\|ch\|ryP	M2fTUnNCVkeHUh?=
NCI-H2171	Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWXUSIYzUUN3ME23PU41OTN4IN88US=>	NULHOm93W0GQR1XS
COLO-668	NHLaZm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRThzLkW4PFQh\|ryP	MWPTRW5ITVJ?
RS4-11	NVPt[W84T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTh{LkK1NFUh\|ryP	NXPvb2k{W0GQR1XS
NCI-H716	M2HwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4C1O2lEPTB;OEKuPVA4PSEQvF2=	M3HVW3NCVkeHUh?=
LU-134-A	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXpZ2JDUUN3ME24N{4yOzVzIN88US=>	NIftfIpUSU6JRWK=
RPMI-8226	NXLOSnlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTh2LkKxNFch\|ryP	NW\WSVB{W0GQR1XS
KY821	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTlzLk[1OVEh\|ryP	M2\kRXNCVkeHUh?=
ECC4	NYfJc\|R1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTl\|LkiyOlkh\|ryP	MojJV2FPT0WU
EW-3	NYXvfHc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfYOZNbUUN3ME25OE46ODhzIN88US=>	M1TjRXNCVkeHUh?=
NB7	NXL5e4hVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PIV2lEPTB;OUWuO\|c5PiEQvF2=	NVLQZVlXW0GQR1XS
NCI-H720	MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mkm3TWM2OD17OD60NFYyKM7:TR?=	NVy3VnVmW0GQR1XS
NCI-H446	NH;IS2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13WUGlEPTB;OUmuO\|U5QCEQvF2=	M1m5SHNCVkeHUh?=
NCI-H889	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjyTWM2OD1zMESuNlQzKM7:TR?=	MnHaV2FPT0WU
EW-22	NFXDZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLLTWM2OD1zME[uNVkh\|ryP	MkTIV2FPT0WU
BV-173	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnJTWM2OD1zMEiuO\|I5KM7:TR?=	MWjTRW5ITVJ?
WSU-NHL	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmXUTWM2OD1zMEmuOlcyKM7:TR?=	M4DjeXNCVkeHUh?=
MN-60	NYm4dpJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkL5TWM2OD1zMEmuOlkh\|ryP	NFXhb25USU6JRWK=
DG-75	M1XmWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY[2XHFVUUN3ME2xNVMvOzV{IN88US=>	NHX1OXJUSU6JRWK=
DMS-79	MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXFVI5KUUN3ME2xNVcvOzh{IN88US=>	M160S3NCVkeHUh?=
SK-MEL-1	M2jpfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTFzOD6wNFkh\|ryP	MV3TRW5ITVJ?
DMS-153	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnob4RGUUN3ME2xNlEvPzR3IN88US=>	NWr6ZnI6W0GQR1XS
NCI-H510A	Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTKTWM2OD1zMkeuN\|Ih\|ryP	NFH2N2NUSU6JRWK=
BE-13	NX3EPZY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33RcWlEPTB;MUO0MlA1PCEQvF2=	MV;TRW5ITVJ?
KP-N-YS	NE\scmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVztOnB4UUN3ME2xN\|kvPzN4IN88US=>	NYn5WXdjW0GQR1XS
SUP-T1	NVfZOXhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVm2NnA5UUN3ME2xOFMvPzB6IN88US=>	MorjV2FPT0WU
EW-12	MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV70O3Q1UUN3ME2xOFQvPjl7IN88US=>	MnzZV2FPT0WU
NB14	NG\XN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTF2Nz6wPFIh\|ryP	NGXVWmZUSU6JRWK=
MDA-MB-134-VI	M{HvR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTF2OD6yOlgh\|ryP	M3PrVHNCVkeHUh?=
NCI-H1770	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\keFZKUUN3ME2xOVYvOjd7IN88US=>	NGjDXmJUSU6JRWK=
TUR	M1vZZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrYeVdKSzVyPUG2O{45PyEQvF2=	NVzpeYVQW0GQR1XS
NCI-H1417	M1S3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{X2d2lEPTB;MUiwMlM{OSEQvF2=	NYfPXlFVW0GQR1XS
IMR-5	M3zl[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXlTWM2OD1zOEGuOVcyKM7:TR?=	NHHOSGJUSU6JRWK=
NCI-H226	NX;5W3dVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfJe5p{UUN3ME2xPFgvQDZ4IN88US=>	NWDWSmJLW0GQR1XS
NCI-H187	M32zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3VbotKSzVyPUG5NE4xPjRizszN	M1rpfnNCVkeHUh?=
SF539	MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzoTWM2OD1zOUKuO\|I5KM7:TR?=	Mnq0V2FPT0WU
TALL-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\p[mlEPTB;MUm4MlMxPCEQvF2=	NEHSd\|RUSU6JRWK=
TE-441-T	NFfFPJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn:zTWM2OD1zOUmuO\|M6KM7:TR?=	NEmxN4tUSU6JRWK=
REH	M{DMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIG0WIRKSzVyPUKzOk43OjZizszN	NXXNdW5tW0GQR1XS
MS-1	M1HVe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{juNWlEPTB;MkO5MlEzOSEQvF2=	NU[0cmEyW0GQR1XS
THP-1	MmD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjzd21SUUN3ME2yOlQvPzN6IN88US=>	MVPTRW5ITVJ?
NCI-H1838	M3vDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7nU\|lIUUN3ME2yO\|EvPDV4IN88US=>	NWT0do9PW0GQR1XS
P30-OHK	M1zhR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TWTmlEPTB;MkizMlg1PyEQvF2=	MnjLV2FPT0WU
C8166	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3oS\|lVUUN3ME2zOFUvOzN6IN88US=>	M2rEcXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western Blot	Bcr-Abl; PubMed: 26722260 Oncol Lett (C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown. Ac-histone H3; PubMed: 26722260 Oncol Lett (C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown. Cleaved-caspase3; PubMed: 26722260 Oncol Lett (C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown. Cleaved-PARP; PubMed: 26722260 Oncol Lett (C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown. ASCL1; PubMed: 19765735 J Surg Res MG-132 decreases the levels of ASCL1 and CgA in carcinoid cancer cells. Pulmonary (NCI-H727) (A) carcinoid cancer cells were treated with MG-132 (0 to 4µM) for 48 hours and cell lysates were analyzed by Western blotting for the expression of ASCL1 and CgA. Treatment with MG-132 results in a dose dependent inhibition of the two neuroendocrine tumor markers. Analysis for GAPDH confirmed equal loading. CgA; PubMed: 19765735 J Surg Res MG-132 decreases the levels of ASCL1 and CgA in carcinoid cancer cells. Pulmonary (NCI-H727) (A) carcinoid cancer cells were treated with MG-132 (0 to 4µM) for 48 hours and cell lysates were analyzed by Western blotting for the expression of ASCL1 and CgA. Treatment with MG-132 results in a dose dependent inhibition of the two neuroendocrine tumor markers. Analysis for GAPDH confirmed equal loading. Nrf2; PubMed: 23604711 Am J Physiol Heart Circ Physiol MG-132 stimulates Nrf2 and HO-1 protein expression in HAECs in a time-dependent fashion. Cells were treated with MG-132 (2 μM) for various times (0–24 h), and Nrf2 and HO-1 protein were quantified by scanning densitometry, normalized with respect to β-actin, and expressed relative to those of control cells. HO-1; PubMed: 23604711 Am J Physiol Heart Circ Physiol MG-132 stimulates Nrf2 and HO-1 protein expression in HAECs in a time-dependent fashion. Cells were treated with MG-132 (2 μM) for various times (0–24 h), and Nrf2 and HO-1 protein were quantified by scanning densitometry, normalized with respect to β-actin, and expressed relative to those of control cells.	26722260 19765735 23604711
Immunofluorescence	C2GnT-M / NMIIA; PubMed: 22525330 Int J Biochem Cell Biol Confocal images of bC2GnT-M and NMIIA in cells treated with DMSO (D) or MG-132 (E). AGS3 / Vimentin; PubMed: 20065032 Mol Cell Biol COS-7 cells were transfected with wild-type or TPR-modified AGS3 (AGS3-TPR [M1 to E470] or AGS3-GPR [E470 to S650]) in pEGFP-N1. Thirty-six hours after transfection, cells were incubated with MG 132 (10 μM) for 12 h, and then the cells were processed for immunofluorescence microscopy. The images presented are representative of 2 to 10 separate transfections. Bak; PubMed: 20557369 Hepatol Res Proteasome inhibitor induces Bak activation. Cells were treated with either vehicle or MG-132 at 10 µmol/L for 12 hours and were subjected to Bak immunofluorescence study using antiserum specific for the N terminus of Bak. Upon Bak activation, this epitope is no longer masked within the protein and becomes available for antibody binding upon Bak conformational change.	22525330 20065032 20557369
Growth inhibition assay	Apoptosis assay; PubMed: 20557369 Hepatol Res LX-2 cells were incubated for 24 hours in the presence of increasing concentrations of MG-132 (0, 2.5, 5, 10 µmol/L) and in the presence of the pan-caspase inhibitor QVD at 5 µmol/L for 24 hours. MG-132 and QVD were prepared in DMSO as a vehicle. All data were expressed as mean ± standard error from three individual experiments. * p < 0.01 (10 µmol/L MG-132 treated cells vs. 10 µmol/L MG-132 plus QVD treated cells) Cell viability; PubMed: 26137056 Oncol Lett The proteasome inhibitor MG-132 significantly decreased the cell viability in EC9706 cells in a dose- and time-dependent manner. cell proliferation ; PubMed: 19765735 J Surg Res MG-132 significantly inhibits growth of carcinoid tumor cells in vitro. Pulmonary (NCI-H727) and GI (BON) carcinoid tumor cells were treated with MG-132 at the indicated concentrations (0 to 4µM) for up to 6 days and cell viability was measured every 2 days with the MTT assay (P<0.001). The results show that MG-132 leads to the suppression cellular proliferation in NCI-H727 (A) and BON (B) cells. (OD, optical density)	20557369 26137056 19765735
ELISA	IL-8; PubMed: 11160671 J Virol ELISA of IL-8 from supernatant of eTat cells. eTat cells were blocked with Hu (2 mM) and released. MG-132 (50 μM) was added at the time of release. The supernatant was collected at 3 h postrelease and analyzed for IL-8 protein using ELISA. The result shown is representative of three independent experiments ± standard deviation. IL-1beta; PubMed: 22606244 PLoS One LPS-primed WT BMDM were incubated in control medium or medium containing 10 ng/ml ricin or 25 µg/ml cycloheximide for 4 h. MG-132 (30 µM) or Bortezimib (0.5 µM) was included as indicated. Secreted IL-1ß was measured by ELISA in triplicate wells.	11160671 22606244

In vivo

Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. ^[7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. ^[8]

Protocol

Kinase Assay: ^[1]	+ Expand Measurement of inhibitory activities of MG-132 against 20S proteasome: The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.
Cell Research: ^[3]	+ Expand Cell lines: KIM-2, HC11, and ES Concentrations: Dissolved in DMSO, final concentrations ~25 μM Incubation Time: 24 and 48 hours Method: Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer. (Only for Reference)
Animal Research: ^[7]	+ Expand Animal Models: Male mdx (C57BL/10ScSn DMD mdx) mice Formulation: Dissolved in DMSO, and diluted in PBS Dosages: ~10 μg/kg/day Administration: Injection (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	90 mg/mL (189.22 mM)
	Ethanol	25 mg/mL (52.56 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+20% propylene glycol+ddH2O For best results, use promptly after mixing.	2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download MG-132 SDF

Molecular Weight	475.62
Formula	C₂₆H₄₁N₃O₅
CAS No.	133407-82-6
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I want to know whether it contains EDTA or other chelating agent in this product(S2619)?
Answer:
Our S2619 MG-132 doesn't contain EDTA or other chelating agent.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Selective Proteasome Inhibitor

CEP-18770 (Delanzomib) : Chymotrypsin-like activity of proteasome, IC50=3.8 nM.
Most Potent Proteasome Inhibitor

Bortezomib (PS-341) : 20S proteasome, K_i of 0.6 nM.
FDA-approved Proteasome Inhibitor

Carfilzomib (PR-171) : Approved by FDA for multiple myeloma.
Newest Proteasome Inhibitor

Oprozomib (ONX 0912) : Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

Related Proteasome Products

VR23 ^New

VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.
Calpeptin ^New

Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.
Marimastat (BB-2516) ^New

Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.
Bortezomib (PS-341)

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with K_i of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
Carfilzomib (PR-171)

Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.
Ixazomib (MLN2238)

MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and K_i of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.
Ixazomib Citrate (MLN9708)

Ixazomib Citrate (MLN9708) immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/K_i of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.
Celastrol

Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

Features:A potent antioxidant and anti-inflammatory drug.
Oprozomib (ONX 0912)

Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Choose Your Country or Region

By Signaling Pathways

By product type